Gómez-Elias CL

Language: Spanish
References: 15
Page: 154-162
PDF size: 547.87 Kb.

ABSTRACT

The bipolar disorder is a chronic mood disorder, characterized by episodes of hypomania or mania and an episode of major depression. Considered a prevalent disease, occasionally with interepisodic dysfunction and associated to high economical cost since the extent of the treatment is indefinite. The suspension of the treatment is connected to a high risk of relapse and reoccurrence, reason why is considered difficult to control. The obstacles for its control increase as finding a pregnant patient due to the gaps that exist in the knowledge during this period. Previously, pregnancy was considered a protective factor in the face of psychiatric diseases; however, recent studies show the opposite. When discussing strategies on the treatment of women planning on pregnancy it is necessary to consider the teratogenic risk against the risk of suspending the effective treatment. The approved medications by the US Food and Drug Administration (FDA) for the treatment of bipolar disorder include lithium, valproate and carbamezapine possess teratogenic side-effects, highlighting among these: Heart malformations, neural tube defects such as spina bifid, craniofacial anomalies, microcephaly and growth restriction.

REFERENCES

1. Gaviria Silvia Lucía. Tratamiento del trastorno afectivo bipolar en el embarazo. Rev Chil Neuro-Psiquiat 2008;46 (1): 43-54

2. Nguyen Ha T. T., Sharma Verinder, McIntyre Roger. Teratogenesis Associated with Antibipolar Agents. Adv Ther (2009) 26 (3):281-294

3. Yonkers Kimberly A., Wisner Katherine L., Stowe Zachary, et al. Management of Bipolar Disorder During Pregnancy and the Postpartum Period. Am J Psychiatry 2004; 161:608-620

4. Viguera Adele C., Whitfield Theodore, Baldessarini Ross J., et al. Risk of Recurrence in Women with Bipolar Disorder During Pregnancy: Prospective Study of Mood Stabilizer Discontinuation. Am J Psychiatry 2007: 164:1817- 1824

5. Correa Eduardo, Holmgren Dagnar. Trastorno bipolar en el periodo reproductivo. Avances en Psiquiatría Biológica 2005; 6: 32-48

6. Sharma Verinder. Management of Bipolar II Disorder during Pregnancy and Postpartum Period. Can J Clin Pharmacol Vol 16 (1) Winter 2009:e33-e41

7. Correa E1, Martínez JC2, Ivanovic-Zuric F3, Uribe D4. Enfermedad bipolar en la mujer en edad fértil. Rev CESMed 2006; 20 (2): 35-52

8. Cohen Lee S. Treatment of Bipolar Disorder During Pregnancy J Clin Psychiatry 2007;68 (suppl 9)

9. Newport Jeffrey, Viguera Adele C., beach Aquila J., Ritchie James C., Cohen Lee S., Stowe Zachary N., Lithium Placental Passage and Obstetrical Outcome: Implications for Clinical Management During Late Pregnancy. Am J Psychiatry 2005; 162:2162-2170

10. Ng F, Mammen OK, Wilting I, Sachs GS, Ferrier IN, Cassidy F, et al. The International Society for Bipolar Disorders (ISBD) Consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord 2009: 11: 559-595

11. Viguera Adele C., Cohen Lee S., Bouffard Suzanne, Whitfield T. Hatch, Baldessarini Ross J., Reproductive Decisions by Women With Bipolar Disorder After Prepregnancy Psychiatric Consultation. Am J Psychiatry 2002: 159: 2102-2104

12. Menon Sharmila J. Psychotropic medication during pregnancy and lactation. Arch Gynecol Obster (2008) 277:1-13

13. Dodd Seetal, Berck Michael. The Safety of Medications for the Treatment of Bipolar Disorder During Pregnancy and the Puerperium. Current Drug Safety, 2006, 1, 25-33

14. Lateef Tarannum Musvee, Nelson Karin B., In Utero Exposure to Antiepileptic Drugs: Teratogenicity and neonatal Morbidity. Current Neurology and Neuroscience Reports 2007, 7:133-138

15. Wieck A., Rao S., Sein K., Haddad P. M. A survey of antiepileptic prescribing to women of childbearing potential in psychiatry. Arch Womens Health (2007) 10: 83-85